{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:51Z","timestamp":1707524331413},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,25]]},"DOI":"10.7759\/cureus.15917","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T14:53:04Z","timestamp":1624632784000},"source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Jaskamal","family":"Padda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khizer","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujala","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounika M","family":"Peethala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Kakani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Goriparthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulelah H","family":"Almanie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayden Charlene","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gutteridge","family":"Jean-Charles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou AN","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018, 19:5-18. 10.2174\/1389201019666180418095526","journal-title":"Curr Pharm Biotechnol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103964","article-title":"The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"345","author":"Feinberg D","year":"2019","unstructured":"Feinberg D, Paul B, Kang Y. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol. 2019, 345:103964. 10.1016\/j.cellimm.2019.103964","journal-title":"Cell Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016, 43:676-81. 10.1053\/j.seminoncol.2016.11.004","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel RL","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016, 66:7-30. 10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7335","article-title":"CAR T cell therapy: a new era for cancer treatment (Review)","volume":"42","author":"Mohanty R","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: a new era for cancer treatment (Review). Oncol Rep. 2019, 42:2183-95. 10.3892\/or.2019.7335","journal-title":"Oncol Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross G","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989, 86:10024-8. 10.1073\/pnas.86.24.10024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5474602","article-title":"CAR T cell therapy: a game changer in cancer treatment","volume":"2016","author":"Alm\u00e5sbak H","year":"2016","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016, 2016:5474602. 10.1155\/2016\/5474602","journal-title":"J Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni L","year":"2017","unstructured":"Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017, 130:2594-602. 10.1182\/blood-2017-06-793869","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek MR","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019, 20:1283. 10.3390\/ijms20061283","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs CS","year":"2013","unstructured":"Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013, 31:999-1008. 10.1038\/nbt.2725","journal-title":"Nat Biotechnol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen AD","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, et al.. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019, 129:2210-21. 10.1172\/JCI126397","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali SA","year":"2016","unstructured":"Ali SA, Shi V, Maric I, et al.. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016, 128:1688-700. 10.1182\/blood-2016-04-711903","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-03592-9","article-title":"Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma","volume":"98","author":"Ma T","year":"2019","unstructured":"Ma T, Shi J, Liu H. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ann Hematol. 2019, 98:813-22. 10.1007\/s00277-018-03592-9","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter RO","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, et al.. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013, 19:2048-60. 10.1158\/1078-0432.CCR-12-2422","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan PR","year":"2002","unstructured":"Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002, 39:1-8. 10.1016\/s0161-5890(02)00094-9","journal-title":"Mol Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik J","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, et al.. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016, 128:384-94. 10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang L","year":"2017","unstructured":"Zhang L, Tai YT, Ho M, et al.. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. Blood Cancer J. 2017, 7:e547. 10.1038\/bcj.2017.24","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi F","year":"2018","unstructured":"Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018, 9:2722. 10.3389\/fimmu.2018.02722","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert J","year":"2014","unstructured":"Deckert J, Wetzel MC, Bartle LM, et al.. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014, 20:4574-83. 10.1158\/1078-0432.CCR-14-0695","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14670\/HH-29.177","article-title":"CD138 (syndecan-1) expression in health and disease","volume":"29","author":"Palaiologou M","year":"2014","unstructured":"Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. Histol Histopathol. 2014, 29:177-89. 10.14670\/HH-29.177","journal-title":"Histol Histopathol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun C","year":"2019","unstructured":"Sun C, Mahendravada A, Ballard B, et al.. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget. 2019, 10:2369-83. 10.18632\/oncotarget.26792","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen","volume":"10","author":"Timmers M","year":"2019","unstructured":"Timmers M, Roex G, Wang Y, et al.. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol. 2019, 10:1613. 10.3389\/fimmu.2019.01613","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2013.10.005","article-title":"Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse","volume":"35","author":"Ramani VC","year":"2014","unstructured":"Ramani VC, Sanderson RD. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014, 35:215-22. 10.1016\/j.matbio.2013.10.005","journal-title":"Matrix Biol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova I","year":"2020","unstructured":"Akhmetzyanova I, McCarron MJ, Parekh S, Chesi M, Bergsagel PL, Fooksman DR. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia. 2020, 34:245-56. 10.1038\/s41375-019-0519-4","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01128","article-title":"Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma","volume":"11","author":"Garc\u00eda-Guerrero E","year":"2020","unstructured":"Garc\u00eda-Guerrero E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front Immunol. 2020, 11:1128. 10.3389\/fimmu.2020.01128","journal-title":"Front Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin Q","year":"2019","unstructured":"Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer. 2019, 18:154. 10.1186\/s12943-019-1092-1","journal-title":"Mol Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall AL","year":"2015","unstructured":"Garfall AL, Maus MV, Hwang WT, et al.. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015, 373:1040-7. 10.1056\/NEJMoa1504542","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh PJ","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021, 11:84. 10.1038\/s41408-021-00469-5","journal-title":"Blood Cancer J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1900351","article-title":"Current advances in chimeric antigen receptor T-cell therapy for refractory\/relapsed multiple myeloma","volume":"21","author":"Huang H","year":"2020","unstructured":"Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T-cell therapy for refractory\/relapsed multiple myeloma. J Zhejiang Univ Sci B. 2020, 21:29-41. 10.1631\/jzus.B1900351","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.04.013","article-title":"Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma","volume":"67","author":"Hutchinson AT","year":"2015","unstructured":"Hutchinson AT, Jones DR, Raison RL. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma. Mol Immunol. 2015, 67:89-94. 10.1016\/j.molimm.2015.04.013","journal-title":"Mol Immunol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos CA","year":"2016","unstructured":"Ramos CA, Savoldo B, Torrano V, et al.. Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains. J Clin Invest. 2016, 126:2588-96. 10.1172\/JCI86000","journal-title":"J Clin Invest"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk J","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, et al.. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012, 42:953-60. 10.1111\/j.1365-2362.2012.02679.x","journal-title":"Eur J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent SA","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH, et al.. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015, 6:7333. 10.1038\/ncomms8333","journal-title":"Nat Commun"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith EL","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M, et al.. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019, 11:eaau7746. 10.1126\/scitranslmed.aau7746","journal-title":"Sci Transl Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila ML","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al.. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014, 6:224ra25. 10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1188\/19.CJON.S1.13-19","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson K","year":"2019","unstructured":"Anderson K, Latchford T. Associated toxicities: assessment and management related to CAR T-cell therapy. Clin J Oncol Nurs. 2019, 23:13-9. 10.1188\/19.CJON.S1.13-19","journal-title":"Clin J Oncol Nurs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo KM","year":"2019","unstructured":"Mahadeo KM, Khazal SJ, Abdel-Azim H, et al.. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol. 2019, 16:45-63. 10.1038\/s41571-018-0075-2","journal-title":"Nat Rev Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran KJ","year":"2012","unstructured":"Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012, 14:405-15. 10.1002\/jgm.2604","journal-title":"J Gene Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant CL","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016, 3:16011. 10.1038\/mto.2016.11","journal-title":"Mol Ther Oncolytics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62273-chimeric-antigen-receptor-t-cell-therapy-and-its-significance-in-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:56Z","timestamp":1707506756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62273-chimeric-antigen-receptor-t-cell-therapy-and-its-significance-in-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.15917","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}